[Results of the 2026 National Talks Released, 107 Drugs Added to the Basic Medical Insurance Catalogue] On November 14, reporters learned from the 2026 High-Quality Development Conference on Innovative Drugs held today that the adjustments to the national basic medical insurance, maternity insurance and work injury insurance drug catalogs in 2026 were officially released. A total of 107 new drugs have been included in this catalog adjustment. These include the world's first approved dual-antibody ADC drug, ilontumumab for injection, Innovent Biologics' Masidotide, Merck's innovative rare disease drug Pimitinib Hydrochloride Capsules, UCB Injection and Rozelixizumab Injection, Dongguang Yang Pharmaceutical's new Class I diabetes drug ologliflozin and other blockbuster innovative drugs. This catalog adjustment is based on following the basics of basic medical insurance, insisting on doing our best and within our capabilities, giving priority to clinical value, taking into account the needs of work-related injury insurance, focusing on key areas such as chronic cancer diseases, mental diseases, rare diseases, and children's medication, focusing on including clinical benefits, clarifying innovative drugs with excellent economic evaluations, and steadily adjusting varieties with strong clinical substitution and low frequency of use. (Reporter Lu Afeng)